Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

Summary

The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted therapies in clinical trials or FDA approved therapies, including "off-label" agents, that result in superior OS compared to historical outcomes for standard CUP therapy.

Conditions

• Neoplasms, Unknown Primary
• CUP
• Metastatic Disease
• Poorly Differentiated Adenocarcinoma
• Poorly Differentiated Carcinoma
• Squamous Carcinoma Poorly Differentiated

Sponsors & Collaborators

• Rush University Medical Center

  collaborator OTHER

• Stormont-Vail Healthcare

  collaborator UNKNOWN

• Jefferson Medical College of Thomas Jefferson University

  collaborator OTHER

• The Cleveland Clinic

  collaborator OTHER

• Sparrow Health System

  collaborator OTHER

• Cancer & Hematology Centers of Western Michigan (CHCWM)

  collaborator UNKNOWN

• Allegheny Health Network

  collaborator OTHER

• St. Luke's Hospital and Health Network, Pennsylvania

  collaborator OTHER

• Solano Hematology Oncology

  collaborator UNKNOWN

• Horizon Oncology Center

  collaborator UNKNOWN

• Comprehensive Blood and Cancer Center

  collaborator OTHER

• Lancaster Cancer Center

  collaborator OTHER

• Western Maryland Health Center

  collaborator UNKNOWN

• Valley Medical Oncology

  collaborator UNKNOWN

• Cape Fear Valley Health System

  collaborator OTHER

• Tri-County Hematology Oncology

  collaborator UNKNOWN

• Hematology & Oncology Associates

  collaborator UNKNOWN

• Broome Oncology

  collaborator UNKNOWN

• Orchard Healthcare

  collaborator UNKNOWN

• Ashland Bellefonte Cancer Center

  collaborator UNKNOWN

• Tennessee Cancer Specialists

  collaborator UNKNOWN

• North Shore Hematology Oncology

  collaborator UNKNOWN

• Good Samaritan

  collaborator UNKNOWN

• Zangmeister Cancer Center

  collaborator UNKNOWN

• Watson clinic

  collaborator UNKNOWN

• Oncology Consultants

  collaborator UNKNOWN

• Oncology Hematology Care

  collaborator UNKNOWN

• Northern Westchester Hospital

  collaborator OTHER

• Peter MacCallum Cancer Center Trials Unit

  collaborator UNKNOWN

• Foundation Medicine

  lead INDUSTRY

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-05-31

Primary Completion

2017-03-31

Completion

2017-03-31

Countries

• United States

Study Locations